Equity Profile
Pre-Earnings Brief
Viking Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for metabolic and endocrine disorders....
EPS
Earnings per share is crucial as it reflects the company's profitability and financial health.
Revenue
Revenue figures are important to gauge the company's sales performance and market demand for its products.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
0Q
EPS Beat Rate
25%
Avg EPS Surprise
-19.44%
Avg Stock Reaction
-0.60%
In Q1-2026, Viking reported an EPS of -$1.37, missing estimates by a significant margin. The stock reacted negatively, declining by 3.27% the following day.
Management Promises & Guidance
Investors are cautious ahead of the upcoming earnings report, especially given the company's recent history of missing EPS estimates. The market is keen to see if Viking can turn around its performance this quarter.
Bull Case
If Viking can demonstrate improved clinical trial results or new partnerships, it could lead to a positive shift in investor sentiment and stock price.
Bear Case
Continued losses and lack of revenue could further erode investor confidence, leading to a decline in stock price.
EPS
N/AEarnings per share is crucial as it reflects the company's profitability and financial health.
Revenue
N/ARevenue figures are important to gauge the company's sales performance and market demand for its products.
Expectations
The print will turn on these two things.
Q1
What specific advancements can Viking report regarding its clinical trials?
Any positive updates could significantly influence investor confidence and stock performance.
Q2
Will there be any guidance on expected revenue streams or partnerships?
Clear guidance on future revenue can help investors gauge the company's growth potential.
Edge
Why consensus could be wrong
The Street may be overly pessimistic about Viking's potential for recovery, given its recent clinical trial results that have not been fully appreciated.
Supporting Evidence
The options market is pricing a significant move, indicating that traders expect volatility that may not align with the company's actual performance.
Viking's historical performance shows potential for recovery, as evidenced by its occasional positive stock reactions despite losses.
Key Risk
If Viking can show any signs of revenue generation or successful trial outcomes, it could shift the narrative significantly.
Edge
Pre-commit to what would confirm each case.
The market is weighing Viking's ability to improve its financial performance and clinical outcomes against its recent history of disappointing results.
Bull Confirmed If
A significant reduction in EPS losses or a positive update on clinical trials would confirm the bull case.
Bear Confirmed If
Continued losses without any revenue guidance would confirm the bear case.
Pre-Earnings Positioning
Implied Move
±28.75%
Historical Avg
±2.8%
The options market is pricing in a significant potential move in either direction, suggesting heightened uncertainty around the earnings report.
Options are pricing ±28.8% while VKTX has averaged ±2.8% over the last 8 prints — setup is pricing rich.
ATM IV
0.7%
30d HV
54.8%
Edge
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing rich in Health Care
n=30Fade rate: 7 of 20 (35%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 20 (65%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 6.4%, with a raw directional average of +3.3% (modestly positive historical bias).
Preparation
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Viking beats expectations, history suggests a potential stock move of around +2.79%, confirming a positive turnaround narrative.
In-Line / Cautious
If results are in line with expectations, the stock may see muted movement as investors await clearer guidance.
Miss
Should Viking miss again, the average reaction suggests a potential decline of around +0.01%, further dampening investor sentiment.
Preparation
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
Southern Copper Corporation